PHARMACEUTICAL IP

Evolve Insights

Welcome to Evolve Insights!

Evolve Insights is your go-to source for expert analysis and strategic perspectives on pharmaceutical IP.

  • Read our Articles for the latest pharma IP news and analysis. Many of our articles were originally published on IPKat.
  • Register for our upcoming live Webinars and watch our previous webinars on-demand.
  • Subscribe to our newsletter to stay up to date.

Do you have questions about how the latest developments in IP might impact you? Our team of experts would love to hear from you.

Latest articles

All articles

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T0883/23)

Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.

CAR-Macrophage (CAR-M) cell therapy: Advantages, challenges, and emerging innovations

Are macrophages the next big thing in cell therapy?

Webinars

All webinars
  • Upcoming

In-person event: Festive EPO pharma case law 2025 round-up

Upcoming date: December 17, 2025, 4:00 pm GMT
Join us for a wrap up review of the key pharma EPO caselaw in 2025 and a look ahead to 2026 alongside some mince pies and festive cheer.
  • Upcoming

EPO pharma case law 2025: Everything you need to know!

Upcoming date: December 12, 2025, 2:00 pm
Key pharma IP trends, landmark EPO decisions, and strategic advice for IP professionals.
  • On-demand

Securing return of investment: Understanding how large pharma companies think about IP

Recorded on: September 19, 2025
Learn how large pharmaceutical companies think about IP strategy.

Stay connected

Get the latest insights, news, and expert analysis on pharmaceutical IP delivered straight to your inbox.
Subscribe for updates